GlassScriptPhysician profile
Rebecca I Weiss
NPI 1609975184
$3,129.20
in general payments reported to CMS, 2019-2025
27 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $183 · 2021: $525 · 2022: $726 · 2023: $179 · 2024: $474 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $675.28 | 2019-2024 | |
| Allergan, INC. | $556.11 | 2019-2022 | |
| Revance Therapeutics, INC. | $395.75 | 2024-2025 | Daxxify |
| Apyx Medical Corporation | $273.61 | 2019-2020 | |
| Abbvie INC. | $244.56 | 2022-2025 | |
| Merz North America, INC. | $236.77 | 2021-2023 | Xeomin |
| Edwards Lifesciences Corporation | $139.51 | 2024 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $134.47 | 2019-2024 | |
| Exact Sciences Corporation | $55.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $47.61 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $37.85 | 2019 | |
| Abbott Laboratories | $37.64 | 2019-2023 | Assurity |
| Novo Nordisk INC | $35.20 | 2023-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $29.08 | 2019-2020 | |
| Lilly USA, LLC | $28.17 | 2020-2025 | Mounjaro, Zepbound |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $23.29 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boston Scientific Corporation | $23.19 | 2022 | |
| Horizon Therapeutics Plc | $19.05 | 2022 | |
| Astellas Pharma US INC | $18.87 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $18.13 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.74 | 2019 | |
| Sonex Health, INC. | $17.14 | 2025 | Sx-One Microknife |
| Lucid Diagnostics INC. | $14.99 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $13.21 | 2023 | |
| Acella Pharmaceuticals, LLC | $12.75 | 2019 | |
| Medtronic Vascular, INC. | $12.17 | 2020 | |
| Vertiflex, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.